These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 23726268)
1. Basic cancer research is essential for the success of personalised medicine. Yarden Y; Caldas C; Eur J Cancer; 2013 Aug; 49(12):2619-20. PubMed ID: 23726268 [TBL] [Abstract][Full Text] [Related]
2. Basic cancer research: why it is essential for the future of cancer therapy. Yarden Y; Caldes C Bull Cancer; 2014 Sep; 101(9):E25-6. PubMed ID: 25295602 [TBL] [Abstract][Full Text] [Related]
3. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736 [TBL] [Abstract][Full Text] [Related]
4. Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. Patel JD; Krilov L; Adams S; Aghajanian C; Basch E; Brose MS; Carroll WL; de Lima M; Gilbert MR; Kris MG; Marshall JL; Masters GA; O'Day SJ; Polite B; Schwartz GK; Sharma S; Thompson I; Vogelzang NJ; Roth BJ J Clin Oncol; 2014 Jan; 32(2):129-60. PubMed ID: 24327669 [TBL] [Abstract][Full Text] [Related]
6. [Clinical research and human and social sciences at Institut National du Cancer (INCa)]. Amsellem N Med Sci (Paris); 2012 Mar; 28 Spec No 1():6. PubMed ID: 22494649 [No Abstract] [Full Text] [Related]
7. Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics. Lee AJ; Swanton C Biochem Pharmacol; 2012 Apr; 83(8):1013-20. PubMed ID: 22192819 [TBL] [Abstract][Full Text] [Related]
9. Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine. Picker A; Jackson DB Expert Rev Mol Diagn; 2011 Jul; 11(6):567-77. PubMed ID: 21745011 [TBL] [Abstract][Full Text] [Related]
10. Disrupting cancer cells' biocircuits with interactome-based drugs: is 'clinical' innovation realistic? Roukos DH Expert Rev Proteomics; 2012 Aug; 9(4):349-53. PubMed ID: 22967071 [No Abstract] [Full Text] [Related]
11. Is there a role of Eastern Europe in cancer biomarkers for personalized cancer medicine? Berindan-Neagoe I; Paradiso A Cancer Biomark; 2014; 14(2-3):85-6. PubMed ID: 24878808 [No Abstract] [Full Text] [Related]
12. Targeted therapy: overcoming drug resistance with clinical cancer genome. Ziogas DE; Katsios CS; Tzaphlidou M; Roukos DH Expert Rev Anticancer Ther; 2012 Jul; 12(7):861-4. PubMed ID: 22845399 [No Abstract] [Full Text] [Related]
13. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics. Parkinson DR; Johnson BE; Sledge GW Clin Cancer Res; 2012 Feb; 18(3):619-24. PubMed ID: 22298894 [TBL] [Abstract][Full Text] [Related]
16. Genome typing of nonhuman primate models: implications for biomedical research. Haus T; Ferguson B; Rogers J; Doxiadis G; Certa U; Rose NJ; Teepe R; Weinbauer GF; Roos C Trends Genet; 2014 Nov; 30(11):482-7. PubMed ID: 24954183 [TBL] [Abstract][Full Text] [Related]
17. Big data in biomedicine. Bender E Nature; 2015 Nov; 527(7576):S1. PubMed ID: 26536215 [No Abstract] [Full Text] [Related]
18. Role of genomics on the path to personalized medicine. Tremblay J; Hamet P Metabolism; 2013 Jan; 62 Suppl 1():S2-5. PubMed ID: 23021037 [TBL] [Abstract][Full Text] [Related]
19. Putting gender on the agenda. Nature; 2010 Jun; 465(7299):665. PubMed ID: 20535156 [No Abstract] [Full Text] [Related]
20. [Nanomedicine as the basis of personalised medicine]. Wojnicz R Kardiol Pol; 2011; 69(10):1107-8. PubMed ID: 22006624 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]